Neutral on Biogen - Analyst Blog NASDAQ Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs ( ABT ), and PEGylated interferon. Biogen's pipeline also has candidates for other ailments like amyotrophic lateral sclerosis (ALS), ... |
